Kallikrein-related peptidase 4: A new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells

American Journal of Pathology

Volumn 176, Issue 3, 2010, Pages 1452-1461

  Gratio, Valérie ^a   Beaufort, Nathalie ^a,b   Seiz, Lina ^b   Maier, Josefine ^b   Virca, G Duke ^c   Debela, Mekdes ^b   Grebenchtchikov, Nicolai ^d   Magdolen, Viktor ^b   Darmoul, Dalila ^a  

^a INSERM   (France)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c AMGEN INC   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 4; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CANCER CELL; COLON ADENOCARCINOMA; COLON CANCER; COLON MUCOSA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION;

EID: 77749245859     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090523     Document Type: Article

References (52)

1. Chung DC: The genetic basis of colorectal cancer: insights into critical pathways of tumorigenesis. Gastroenterology 2000, 119:854-865
2. Wong J, Hawkins N, Ward R: Colorectal cancer: a model for epigenetic tumorigenesis. Gut 2007, 56:140-148
3. Mook OR, Frederiks WM, Van Noorden CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004, 1705:69-89
4. Lopez-Otin C, Matrisian LM: Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007, 7:800-808
5. Dery O, Corvera CU, Steinhoff M, Bunnett NW: Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol 1998, 274:C1429-C1452
6. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R: Proteinaseactivated receptors. Pharmacol Rev 2001, 53:245-282
7. Ramsay AJ, Reid JC, Adams MN, Samaratunga H, Dong Y, Clements JA, Hooper JD: Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs). Biol Chem 2008, 389:653-668
8. Hollenberg MD, Oikonomopoulou K, Hansen KK, Saifeddine M, Ramachandran R, Diamandis EP: Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer. Biol Chem 2008, 389:643-651
9. Ossovskaya VS, Bunnett NW: Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004, 84:579-621
10. Hollenberg MD, Compton SJ: International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors. Pharmacol Rev 2002, 54:203-217
11. Darmoul D, Marie JC, Devaud H, Gratio V, Laburthe M: Initiation of human colon cancer cell proliferation by trypsin acting at proteaseactivated receptor-2. Br J Cancer 2001, 85:772-779
12. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M: Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003, 162:1503-1513
13. Gratio V, Walker F, Lehy T, Laburthe M, Darmoul D: Aberrant expression of proteinase-activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB-2 kinase. Int J Cancer 2009, 124:1517-1525
14. Darmoul D, Gratio V, Devaud H, Laburthe M: Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 2004, 279:20927-20934
15. Darmoul D, Gratio V, Devaud H, Peiretti F, Laburthe M: Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation. Mol Cancer Res 2004, 2:514-522
16. Ramachandran R, Hollenberg MD: Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol 2008, 153:S263-S282
17. Knecht W, Cottrell GS, Amadesi S, Mohlin J, Skaregarde A, Gedda K, Peterson A, Chapman K, Hollenberg MD, Vergnolle N, Bunnett NW: Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia. J Biol Chem 2007, 282:26089-26100
18. Cottrell GS, Amadesi S, Grady EF, Bunnett NW: Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 2004, 279:13532-13539
19. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Diamandis EP, Hollenberg MD: Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. Biol Chem 2006, 387:677-685
20. Stefansson K, Brattsand M, Roosterman D, Kempkes C, Bocheva G, Steinhoff M, Egelrud T: Activation of proteinase-activated receptor-2 by human kallikrein-related peptidases. J Invest Dermatol 2008, 128:18-25
21. Ramsay AJ, Dong Y, Hunt ML, Linn M, Samaratunga H, Clements JA, Hooper JD: Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs). KLK4 and PAR-2 are co-expressed during prostate cancer progression J Biol Chem 2008, 283:12293-12304
22. Mize GJ, Wang W, Takayama TK: Prostate-specific kallikreins-2 and -4 enhance the proliferation of DU-145 prostate cancer cells through protease-activated receptors-1 and -2. Mol Cancer Res 2008, 6:1043-1051
23. Borgono CA, Michael IP, Diamandis EP: Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004, 2:257-280
24. Obiezu CV, Shan SJ, Soosaipillai A, Luo LY, Grass L, Sotiropoulou G, Petraki CD, Papanastasiou PA, Levesque MA, Diamandis EP: Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 2005, 51:1432-1442
25. Borgono CA, Diamandis EP: The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004, 4:876-890
26. Debela M, Beaufort N, Magdolen V, Schechter NM, Craik CS, Schmitt M, Bode W, Goettig P: Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7. Biol Chem 2008, 389:623-632
27. Debela M, Magdolen V, Schechter N, Valachova M, Lottspeich F, Craik CS, Choe Y, Bode W, Goettig P: Specificity profiling of seven human tissue kallikreins reveals individual subsite preferences. J Biol Chem 2006, 281:25678-25688
28. Brass LF, Vassallo RR Jr, Belmonte E, Ahuja M, Cichowski K, Hoxie JA: Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. J Biol Chem 1992, 267:13795-13798
29. Beaufort N, Debela M, Creutzburg S, Kellermann J, Bode W, Schmitt M, Pidard D, Magdolen V: Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol Chem 2006, 387:217-222
30. McKiernan E, O'Brien K, Grebenchtchikov N, Geurts-Moespot A, Sieuwerts AM, Martens JW, Magdolen V, Evoy D, McDermott E, Crown J, Sweep FC, Duffy MJ: Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA. Br J Cancer 2008, 99:1644-1650
31. Debela M, Magdolen V, Grimminger V, Sommerhoff C, Messerschmidt A, Huber R, Friedrich R, Bode W, Goettig P: Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site. J Mol Biol 2006, 362:1094-1107
32. Shaw JL, Diamandis EP: Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 2007, 53:1423-1432
33. French bioethics law, no. 2004-800. August 6, 2004, Art. L. 1232-1, Art. L. 1235-2, Art. L. 1245-2
34. Trejo J: Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking. J Pharmacol Exp Ther 2003, 307:437-442
35. Hollenberg MD, Saifeddine M, al-Ani B, Kawabata A: Proteinaseactivated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides. Can J Physiol Pharmacol 1997, 75:832-841
36. Nitschke R, Leipziger J, Greger R: Agonist-induced intracellular Ca2+ transients in HT29 cells. Pflugers Arch 1993, 423:519-526
37. Kontos C, Papadopoulos I, Scorilas A: Quantitative expression analysis and prognostic significance of KLK4 mRNA expression in colon cancer. Tissue Kallikrein and Kallikrein-Related Peptidase: Biochemistry, Structure, Function, and (Patho)physiology. Edited by Schmitt MFH, Sommerhoff C, Magdolen V. Hieronymus Druck und Verlag, Munich, p86, 2009
38. Yousef GM, Borgono CA, Popalis C, Yacoub GM, Polymeris ME, Soosaipillai A, Diamandis EP: In-silico analysis of kallikrein gene expression in pancreatic and colon cancers. Anticancer Res 2004, 24:43-51
39. Obiezu CV, Soosaipillai A, Jung K, Stephan C, Scorilas A, Howarth DH, Diamandis EP: Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 2002, 48:1232-1240
40. Obiezu CV, Scorilas A, Katsaros D, Massobrio M, Yousef GM, Fracchioli S, Rigault de la Longrais IA, Arisio R, Diamandis EP: Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 2001, 7:2380-2386
41. Pampalakis G, Diamandis EP, Sotiropoulou G: The epigenetic basis for the aberrant expression of kallikreins in human cancers. Biol Chem 2006, 387:795-799
42. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K: Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001, 40:15341-15348
43. Clements JA, Willemsen NM, Myers SA, Dong Y: The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004, 41: 265-312
44. Al-Ani B, Hollenberg MD: Selective tryptic cleavage at the tethered ligand site of the amino terminal domain of proteinase-activated receptor-2 in intact cells. J Pharmacol Exp Ther 2003, 304: 1120-1128
45. Kawabata A, Saifeddine M, Al-Ani B, Leblond L, Hollenberg MD: Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. J Pharmacol Exp Ther 1999, 288:358-370
46. Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang HC, Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ, McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE, White KB: Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA 1999, 96:12257-12262
47. Trejo J, Connolly AJ, Coughlin SR: The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice. J Biol Chem 1996, 271:21536-21541
48. Compton SJ, Renaux B, Wijesuriya SJ, Hollenberg MD: Glycosylation and the activation of proteinase-activated receptor 2 (PAR(2)) by human mast cell tryptase. Br J Pharmacol 2001, 134:705-718
49. Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR: Domains specifying thrombin-receptor interaction. Nature 1991, 353:674-677
50. Ramachandran R, Mihara K, Mathur M, Rochdi M, Bouvier M, Defea K, Hollenberg MD: Agonist-biased signaling via proteinase activated receptor-2: differential activation of calcium and mitogen-activated protein kinase pathways. Mol Pharmacol 2009, 76:791-801
51. Russo A, Soh UJ, Trejo J: Proteases display biased agonism at protease-activated receptors: location matters! Mol Interv 2009, 9:87-96
52. Russo A, Soh UJ, Paing MM, Arora P, Trejo J: Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc Natl Acad Sci USA 2009, 106:6393-6397